Weight gain is a persisting issue with diabetic therapies. It results from increased availability of insulin which is an anabolic (stores energy) hormone. Some diabetic medications also cause water retention.

The FDA recently approved two new diabetic medications for the treatment of diabetes. These medications in addition to improving diabetes control appear to cause progressive weight reduction. These drugs mimic glucose-lowering action produced by human incretins normally produced by the gastrointestinal tract in response to nutrient entry.

One of the drugs Exenatide (byetta) used in patients with Type 2 diabetes appears to achieve sustained glucose control and average weight reduction of 12 lbs after 18 months of therapy. Pramlinitide acetate (Symlin) has been approved for adjunctive use with insulin in patients with Type 1 and 2 diabetes. Weight reduction of 3.6% was reported after 16 wks.

Metformin (Glucophage) an oral agent available since 1994 has the ability to induce weight loss when used alone or in combination with other drugs. These drugs can have serious side effects and are not indicated for weight loss in the general population. They should be used under the supervision of a physician.

Wasima Masoodi, M.D
Diplomat, American Board of Internal Medicine and Endocrinology
Member, South Bay Independent Physicians Medical Group, Inc.